Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03693170 · ClinicalTrials.gov registry record · Phase 2
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
A Phase 2 study, sponsored by Pierre Fabre Medicament.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT03693170 is a Phase 2 study that has completed, run by Pierre Fabre Medicament. The registered enrollment target is 95 participants.
The verdict
NCT03693170, a Phase 2 study, has completed, sponsored by Pierre Fabre Medicament.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
Interventions
- DRUG Cetuximab
- DRUG Binimetinib
- DRUG encorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2019-01-17 |
| Est. Completion | 2023-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03693170
The ClinicalTrials.gov registry entry for NCT03693170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pierre Fabre Medicament, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT03693170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03693170 about?
NCT03693170 is a clinical study titled "Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer". The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
What is the current status of trial NCT03693170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2019-01-17. Estimated completion is 2023-04-27.
What interventions are being tested in trial NCT03693170?
The interventions under investigation include: Cetuximab (DRUG), Binimetinib (DRUG), encorafenib (DRUG).
Who is sponsoring clinical trial NCT03693170?
This trial is sponsored by Pierre Fabre Medicament, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.